Several factors that affect optimal use of evidence-based medical therapy are within the control of providers.
Randomized trials have established a strong evidence base for the efficacy of a relatively large number of pharmacotherapies for heart failure, but contemporary drug regimens are costly and complex. Might patient nonadherence be a critical barrier to achieving the full clinical potential of important research? To find out, investigators studied data from 107,092 adults who survived a first hospitalization for HF between 1995 and 2004 in Denmark.
Based on prescriptions claimed, treatment was initiated within 90 days of discharge with renin-angiotensin inhibitors (ACE inhibitors or angiotensin-receptor blockers) in 43% of patients, with beta-blockers in 27%, with spironolactone in 19%, and with statins in 12%. Between 90 days and 1 year, the p…
Reviewing Author
DisclosuresConsultant/Advisory BoardBristol Myers Squibb; CPC Clinical Research
Grant/Research SupportNational Heart, Lung, and Blood Institute
Editorial BoardsUpToDate; American College of Cardiology Self-Assessment Program (SAP)
Leadership Positions in Professional SocietiesAmerican College of Cardiology (Chair, Innovations Committee)
DisclosuresConsultant/Advisory BoardBristol Myers Squibb; CPC Clinical Research
Grant/Research SupportNational Heart, Lung, and Blood Institute
Editorial BoardsUpToDate; American College of Cardiology Self-Assessment Program (SAP)
Leadership Positions in Professional SocietiesAmerican College of Cardiology (Chair, Innovations Committee)